NCT01186198已完成不适用
A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 4
- 主要终点
- Percentage of Participants With Procedure Success
研究概览
简要总结
This is a prospective, single-arm, open-label, multi-center, observational study to assess the acute safety and efficacy of MINI TREK RX 1.20 mm for enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria
- •Subject must be at least 18 years of age.
- •Subject or a legally authorized representative must provide written informed consent prior to any study related procedure.
- •Subject must have stenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention.
- •Subject must have single or multiple vessel coronary artery disease with clinical evidence of myocardial ischemia (e.g., stable or unstable angina or silent ischemia documented by a positive functional study).
- •Subject must be an acceptable candidate for CABG.
- •Subject must agree to undergo all protocol-required follow-up procedures.
- •Subject must agree not to participate in any other clinical study during hospitalization for the index procedure.
- •Angiographic Inclusion Criteria
- •All angiographic inclusion criteria are based on visual estimation.
- •De novo or restenotic lesions in native coronary arteries or bypass grafts.
- •A maximum of two lesions, including at least one target lesion, in up to two major epicardial distribution trees. Tandem lesions, defined as multiple, focal lesions that can be covered by one stent, will be considered as a single lesion.
- •If one target lesion and one non-target lesion are to be treated, the target and non-target lesions must be located in different major epicardial distribution trees.
- •The target lesion must have a diameter stenosis of ≥ 70% by visual estimation or online quantitative coronary angiography (QCA), which may include chronic total occlusion (CTO).
- •Lesions may be located in highly tortuous vessels.
排除标准
- •General Exclusion Criteria
- •Subject has had a known diagnosis of an acute myocardial infarction (AMI) within 72 hours preceding the intended index procedure.
- •The subject is currently experiencing clinical symptoms consistent with a new onset of AMI, such as prolonged chest pain with ischemic ECG changes unresponsive to nitrates.
- •Subject has hemodynamic instability or any hemodynamically unstable cardiac arrhythmias.
- •Subject has a known left ventricular ejection fraction (LVEF) < 30% at the most recent evaluation (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary).
- •Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).
- •Subject will require Low Molecular Weight Heparin (LMWH) within 8 hours before or at any time after the index procedure.
- •Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-medicated.
- •Subject has a platelet count < 100,000 cells/mm^3 or > 700,000 cells/mm^
- •Subject has a serum creatinine level > 2.0 mg/dl within seven days prior to index procedure.
- •Subject has had a cerebrovascular accident/stroke or transient ischemic neurological attack (TIA) within the past six months.
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- •Subject has had active peptic ulcer or a significant gastrointestinal or urinary bleed within the past six months.
- •Elective surgery is planned during hospitalization for the index procedure that will require discontinuing dual anti-platelet therapy.
- •Subject has other medical illness (e.g., cancer) that may confound the data interpretation or is associated with a limited life expectancy.
- •Subject is currently participating in an investigational study when such participation could confound the treatment or outcomes of this study.
- •Subject is pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- •Angiographic Exclusion Criteria
- •All angiographic exclusion criteria are based on visual estimation.
- •More than two lesions require treatment. Tandem lesions, defined as multiple, focal lesions that can be covered by one stent, will be considered as a single lesion.
- •Target lesion is located in an unprotected left main artery.
- •Coronary artery spasm in the absence of significant stenosis.
- •Target vessel contains thrombus as indicated in the initial angiographic images.
- •During the index procedure, any lesion requires additional treatment with any adjunctive or ablative device (i.e., rotational or directional atherectomy, cutting balloon, laser, thrombectomy, etc.).
- •Target lesion involving a bifurcation with a side branch ≥ 2.5 mm in diameter, with an ostial lesion > 40% stenosed, or with a side branch requiring protection guide wire or pre-dilatation.
- •Additional clinically significant lesion(s) in any coronary arteries or bypass grafts for which PCI may be required during hospitalization for the index procedure.
结局指标
主要结局
Percentage of Participants With Procedure Success
时间窗: On Day 0 (From the start to end of the interventional procedure)
Procedure success was defined as meeting all the following after single or multiple attempts: 1. Successful delivery of the MINI TREK RX 1.20 mm balloon to and across the target lesion, 2. Successful inflation and deflation with the MINI TREK RX 1.20 mm balloon, 3. No vessel perforation, no flow-limiting vessel dissection, no reduction in TIMI flow from baseline, and no clinically significant arrhythmias requiring medical treatment or device intervention following dilatation with the MINI TREK RX 1.20 mm balloon, and 4. Achieve a final TIMI flow grade of 3 at the conclusion of the PCI procedure for the lesion.
次要结局
- Rate of Device Success(On Day 0 (From the start to end of the interventional procedure))
- Rate of Target Lesion Failure (TLF)(In-Hospital (1 - 3 Days))
- Rate of Individual Procedural Parameters(On Day 0 (From the start to end of the interventional procedure))
- Rate of Major Adverse Cardiac Event (MACE)(In-Hospital (1 - 3 Days))
- Rate of Stent Thrombosis(In-Hospital (1 - 3 Days))
- Rate of Lesion Success(On Day 0 (From the start to end of the interventional procedure))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesLateral Canthal LinesCrow's FeetFacial WrinklesNCT00888914Revance Therapeutics, Inc.60
已完成
2 期
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesLateral Canthal LinesNCT00907387Revance Therapeutics, Inc.72
已完成
2 期
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal LinesLateral Canthal LinesCrow's FeetFacial WrinklesNCT00968825Revance Therapeutics, Inc.73
已完成
1 期
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable CancerSolid CancersNCT00927589Genentech, Inc.59
Unknown
不适用
VitaFlow™ Transcatheter Aortic Valve System Pre-market TrialAortic Valve StenosisNCT04655742Shanghai MicroPort CardioFlow Medtech Co., Ltd.120